Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Next-generation glaucoma therapeutics hold considerable promise

08.04.2014

Elevated pressure in the eye is the most common risk factor for glaucoma, an optic neuropathy that can cause blindness and affects more than 67 million people worldwide.

Elevated eye pressure in glaucoma develops due to abnormal functioning of the trabecular meshwork (TM) causing intraocular fluid to back up. Next-generation glaucoma drugs will target the finely tuned mechanisms of the TM that maintain normal intraocular pressure, as described in an article in Journal of Ocular Pharmacology and Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article, one of 25 articles in a special double issue of the Journal, is available free on the Journal of Ocular Pharmacology and Therapeutics website.


Celebrating 30 years in 2014, Journal of Ocular Pharmacology and Therapeutics is an authoritative peer-reviewed journal published ten times a year online with Open Access options and in print. It is the only multidisciplinary, peer-reviewed journal providing basic and clinical research that focuses on biopharmaceuticals that have the potential to prevent, treat, and/or diagnose ocular diseases and disorders. The Journal delivers the latest discoveries in the pharmacokinetics and pharmacodynamics of biopharmaceuticals for the treatment of ophthalmic disorders. Journal of Ocular Pharmacology and Therapeutics is the Official Journal of the Association for Ocular Pharmacology and Therapeutics. Complete tables of content and a sample issue may be viewed on the Journal of Ocular Pharmacology and Therapeutics website.

Credit: © Mary Ann Liebert, Inc., publishers

The article "Intraocular Pressure Homeostasis: Maintaining Balance in a High-Pressure Environment," by Ted Acott and coauthors, Oregon Health & Science University, Portland, OR, describes the efficient mechanisms at work in the eye to keep intraocular pressure within an acceptable range for 92-98% of the population. Understanding these mechanisms will enable the development of drug interventions to treat the unfortunate 2-8% of people that are at risk of developing elevated eye pressure and glaucoma.

"The TM, a unique multilayered tissue that controls intraocular pressure, and its surrounding structures represent viable targets for the development of novel glaucoma therapies," write Editor-in-Chief W. Daniel Stamer, PhD, Duke University (Durham, NC) and Guest Editor John R. Samples, MD, Professor, Rocky Vista University and Director, Western Glaucoma Foundation, Portland, OR, in the Editorial "The Trabecular Meshwork Special Issue, Inspired by the TM Study Club."

The special double issue provides a comprehensive look at the TM and next-generation glaucoma therapies in development through a collection of editorials, original research articles, and reviews. Included is the review article "The Role of TGF-ß2 and Bone Morphogenetic Proteins in the Trabecular Meshwork and Glaucoma," in which Robert Wordinger, Tasneem Sharma, and Abbot Clark, University of North Texas Health Science Center, Fort Worth, describe the TGF-ß superfamily of growth factors and their role in primary open-angle glaucoma (POAG), the second leading cause of blindness worldwide.

Also of note, Nelson Winkler, Mayo Clinic College of Medicine, and Michael Fautsch, Mayo Clinic, Rochester, MN, explore the current understanding of how prostaglandin analogues, first-line treatments for glaucoma, work to reduce elevated intraocular pressure, in the review article "Effects of Prostaglandin Analogues on Aqueous Humor Outflow Pathways."

###

About the Journal

Celebrating 30 years in 2014, Journal of Ocular Pharmacology and Therapeutics is an authoritative peer-reviewed journal published ten times a year online with Open Access options and in print. It is the only multidisciplinary, peer-reviewed journal providing basic and clinical research that focuses on biopharmaceuticals that have the potential to prevent, treat, and/or diagnose ocular diseases and disorders. The Journal delivers the latest discoveries in the pharmacokinetics and pharmacodynamics of biopharmaceuticals for the treatment of ophthalmic disorders. Journal of Ocular Pharmacology and Therapeutics is the Official Journal of the Association for Ocular Pharmacology and Therapeutics. Complete tables of content and a sample issue may be viewed on the Journal of Ocular Pharmacology and Therapeutics website.

About the Publisher Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Assay and Drug Development Technologies and Population Health Management. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

Vicki Cohn | EurekAlert!

More articles from Life Sciences:

nachricht A new potential biomarker for cancer imaging
05.02.2016 | Universiti Putra Malaysia (UPM)

nachricht NIH researchers identify striking genomic signature shared by 5 types of cancer
05.02.2016 | NIH/National Human Genome Research Institute

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Automated driving: Steering without limits

OmniSteer project to increase automobiles’ urban maneuverability begins with a € 3.4 million budget

Automobiles increase the mobility of their users. However, their maneuverability is pushed to the limit by cramped inner city conditions. Those who need to...

Im Focus: Microscopy: Nine at one blow

Advance in biomedical imaging: The University of Würzburg's Biocenter has enhanced fluorescence microscopy to label and visualise up to nine different cell structures simultaneously.

Fluorescence microscopy allows researchers to visualise biomolecules in cells. They label the molecules using fluorescent probes, excite them with light and...

Im Focus: NASA's ICESat-2 equipped with unique 3-D manufactured part

NASA's follow-on to the successful ICESat mission will employ a never-before-flown technique for determining the topography of ice sheets and the thickness of sea ice, but that won't be the only first for this mission.

Slated for launch in 2018, NASA's Ice, Cloud and land Elevation Satellite-2 (ICESat-2) also will carry a 3-D printed part made of polyetherketoneketone (PEKK),...

Im Focus: Sinking islands: Does the rise of sea level endanger the Takuu Atoll in the Pacific?

In the last decades, sea level has been rising continuously – about 3.3 mm per year. For reef islands such as the Maldives or the Marshall Islands a sinister picture is being painted evoking the demise of the island states and their cultures. Are the effects of sea-level rise already noticeable on reef islands? Scientists from the ZMT have now answered this question for the Takuu Atoll, a group of Pacific islands, located northeast of Papua New Guinea.

In the last decades, sea level has been rising continuously – about 3.3 mm per year. For reef islands such as the Maldives or the Marshall Islands a sinister...

Im Focus: Energy-saving minicomputers for the ‘Internet of Things’

The ‘Internet of Things’ is growing rapidly. Mobile phones, washing machines and the milk bottle in the fridge: the idea is that minicomputers connected to these will be able to process information, receive and send data. This requires electrical power. Transistors that are capable of switching information with a single electron use far less power than field effect transistors that are commonly used in computers. However, these innovative electronic switches do not yet work at room temperature. Scientists working on the new EU research project ‘Ions4Set’ intend to change this. The program will be launched on February 1. It is coordinated by the Helmholtz-Zentrum Dresden-Rossendorf (HZDR).

“Billions of tiny computers will in future communicate with each other via the Internet or locally. Yet power consumption currently remains a great obstacle”,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

AKL’16: Experience Laser Technology Live in Europe´s Largest Laser Application Center!

02.02.2016 | Event News

From intelligent knee braces to anti-theft backpacks

26.01.2016 | Event News

DATE 2016 Highlighting Automotive and Secure Systems

26.01.2016 | Event News

 
Latest News

A new potential biomarker for cancer imaging

05.02.2016 | Life Sciences

Graphene is strong, but is it tough?

05.02.2016 | Materials Sciences

Tiniest Particles Shrink Before Exploding When Hit With SLAC's X-ray Laser

05.02.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>